Nurix Therapeutics

We are pleased to share that the European Medicines Agency (EMA) has granted PRIME designation for NX-5948 for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).?? ? The EMA’s PRIME initiative offers early, proactive, and enhanced support to developers of promising medicines to optimize development plans and accelerate evaluation so these medicines can reach patients faster.? ? Learn more here: https://bit.ly/4fzMjm9

Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will present a corporate update at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:30 a.m. GMT. Listen to the live or archived presentation here:?https://lnkd.in/gTBNxVc4

Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will present a company overview at the Stifel Healthcare Conference on Monday, November 18, 2024, at 4:45 p.m. ET. Listen to the live or archived presentation here:?https://lnkd.in/gVghWj76

Today, at the American College of Rheumatology (ACR) Convergence 2024, we presented preclinical data in two posters demonstrating the potential superiority of our targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases.?? ? The posters highlight preclinical data from two autoimmune and inflammatory disease programs: NX-5948, our proprietary, orally available, brain penetrant BTK degrader, and GS-6791, a selective, orally bioavailable degrader of IRAK4 which is being developed in collaboration with Gilead Sciences.?? ? Learn more here: https://bit.ly/48VUW87

We were honored to sponsor the The Leukemia & Lymphoma Society's Light The Night event in San Francisco, joining together to support those impacted by blood cancers.?? ? Our mission to develop innovative targeted protein modulation therapeutics to potentially improve the outcomes of those with cancer and other challenging diseases aligns closely with the purpose of this inspiring event—bringing hope, advancing research, and standing with patients and their families.?? ? We are grateful for our team members who came out to light the night and illuminate the path toward a brighter future for all affected by cancer.?? ? #LightTheNight

Nurix’s President and CEO, Arthur T. Sands, M.D., Ph.D., will discuss the latest company updates in a fireside chat at the the Stephens Biotechnology Virtual Fireside Chats on Thursday, November 14, 2024, at 2:30 p.m. ET. Be sure to tune in if you’re attending the conference.

Nurix’s Chief Scientific Officer, Gwenn Hansen, Ph.D., will discuss how Nurix is deploying its innovative targeted protein modulation platform to develop novel therapeutics in a presentation at the SMART Symposium on Wednesday, November 13, 2024, at 2:00 p.m. CST in Shenzhen, China. Learn more here: https://bit.ly/40wMGcq

Nurix’s Chief Financial Officer, Hans van Houte, and Chief Business Officer, Jason Kantor, Ph.D., will discuss the latest company updates in a fireside chat at the UBS Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m. PT. Listen to the live or archived discussion here:?https://lnkd.in/g-Bm2cR8

Nurix’s President and Chief Executive Officer, Arthur T. Sands, M.D., Ph.D., will participate in a panel discussion at the Truist BioPharma Symposium on Thursday, November 7, 2024, at 10:30 a.m. ET. Be sure to tune in if you’re attending the conference.

More than 234,000 people in the US will be diagnosed with lung cancer this year. At Nurix, we’re using our targeted protein modulation platform to potentially improve outcomes for those facing a diagnosis of cancer, including lung cancer. Learn more about our work here: https://bit.ly/3L7kMKK #LungCancerAwareness?